How Supplement Regulation Works in the U.S.: 2026 Guide

Dietary supplements in the United States are regulated primarily under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which classifies them as a category of food rather than drugs. The FDA does not approve supplements for safety or effectiveness before they reach store shelves. Instead, manufacturers bear the legal responsibility for ensuring their products are safe and accurately labeled. Here is the core of how the system works:

• Supplements are regulated as food, not drugs, under the Federal Food, Drug, and Cosmetic Act as amended by DSHEA.
• The FDA cannot require pre-market approval; its enforcement is largely reactive, acting after a product is already on the market.
• Manufacturers must follow Current Good Manufacturing Practices (CGMP) under 21 CFR part 111.
• Labels must carry a Supplement Facts panel and be truthful, not misleading.
• Supplements cannot legally claim to treat, prevent, or cure any disease.
• The Federal Trade Commission (FTC) oversees advertising claims separately from the FDA’s labeling authority.
• The Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH) supports research and consumer education.
• New dietary ingredients (NDIs) introduced after October 15, 1994 require a safety notification to the FDA before marketing.
• Manufacturers must report serious adverse events to the FDA within 15 days of receiving them.

Table of Contents

• How the legal framework governs dietary supplements
• What federal agencies actually do to oversee supplements
• How CGMP rules protect supplement quality
• How supplement labeling and marketing claims work
• Where the regulatory system falls short
• What you should actually do as a supplement consumer
• What Mycelia Link sees in the supplement industry
• How other countries regulate supplements compared to the U.S.
• Key Takeaways

How the legal framework governs dietary supplements

The legal backbone of supplement regulation is the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically as amended by DSHEA in 1994. Before DSHEA, the FDA had broader authority to restrict supplements. The 1994 law shifted the balance significantly toward manufacturer responsibility and away from pre-market government approval.

Under DSHEA, a dietary supplement is defined as a product intended to supplement the diet that contains one or more of the following: a vitamin, mineral, herb or botanical, amino acid, or a dietary substance used to supplement the diet by increasing total dietary intake. This classification as food, rather than a drug, is the single most consequential fact in understanding how supplements are regulated.

• The FDA cannot require proof of safety or effectiveness before a supplement goes to market.
• Manufacturers and distributors are legally responsible for evaluating safety and labeling before marketing their products.
• A product intended to treat, prevent, or cure a disease is legally classified as a drug, regardless of how it is labeled.
• New dietary ingredients (those not marketed in the U.S. before October 15, 1994) require manufacturers to notify the FDA with safety evidence before marketing.
• The presumption of safety applies only to ingredients with a documented history of use before that 1994 cutoff date.
• The FD&C Act gives the FDA authority to deem products adulterated or misbranded and take enforcement action after market entry.
• DSHEA also explicitly excludes any ingredient that is an active component of an approved drug from being marketed as a supplement, unless it was sold as a supplement before that drug approval.

The drug-versus-supplement distinction often comes down to intended use, which manufacturers typically signal through their own labeling and marketing language. That creates a gray area the FDA must navigate case by case, and it is one reason consumer confusion is so common.

What federal agencies actually do to oversee supplements

Three agencies share responsibility for supplement oversight, each with a distinct lane.

The FDA is the primary regulator. Its work on dietary supplements is coordinated by the Human Foods Program’s Office of Food Chemical Safety, Dietary Supplements, and Innovation. The FDA regulates both finished supplement products and dietary ingredients, covering manufacturing, labeling, safety monitoring, and post-market enforcement. Its model is reactive by design: the agency acts after a product is on the market, not before.

• The FDA conducts facility inspections and evaluates adverse event reports to identify safety problems.
• It can issue warning letters, request voluntary recalls, or order mandatory recalls under specified circumstances.
• It can deem a product adulterated or misbranded and pursue enforcement action, including market removal.
• The FDA does not have authority to require pre-market testing or approve supplement formulas.

The FTC handles advertising. While the FDA governs what appears on a product label, the FTC regulates advertising claims in commercials, online marketing, and promotional materials to prevent deceptive practices. A company can face FTC action for making claims in an ad that would also be prohibited on a label.

The ODS at NIH does not regulate products directly. Instead, it funds research on supplement safety and efficacy, publishes consumer fact sheets, and advises the public to consult healthcare professionals before using supplements, given that testing standards for supplements are less rigorous than those applied to drugs.

How CGMP rules protect supplement quality

Current Good Manufacturing Practices, codified in 21 CFR part 111, are the primary quality control mechanism for supplements. The FDA finalized these rules in June 2007, and they apply to anyone who manufactures, packages, labels, or holds a dietary supplement, including contractors.

CGMP requirements are not suggestions. They carry the full force of law.

• Manufacturers must establish and follow written procedures covering all stages of production, packaging, labeling, and holding.
• Every dietary ingredient must undergo at least one test or examination to verify its identity before use.
• Master manufacturing records must document specifications for each product batch.
• Quality control personnel must approve or reject all processes, specifications, and deviations that could affect a product’s identity, purity, strength, or composition.
• A finished batch must be verified against product specifications before release.
• A supplement produced under conditions that do not meet CGMP standards is legally considered adulterated, even if the product itself tests clean.

Post-market safety monitoring runs alongside CGMP enforcement. The FDA relies on the CFSAN Adverse Event Reporting System (CAERS) to track reports submitted by manufacturers, healthcare providers, and the public. Manufacturers are legally required to submit reports of serious adverse events within 15 days. Public submissions remain voluntary, which creates a known gap in the data. An analysis of CAERS data covering 2004 through 2013 found that FDA received more than 15,000 adverse event reports during that period, with 67% classified as mandatory industry reports. Understanding why contaminated products still reach consumers despite these rules is something Mycelia Link covers in depth in its guide on why contaminated supplements reach shelves.

How supplement labeling and marketing claims work

Every supplement sold in the U.S. must carry a Supplement Facts panel. Under 21 CFR § 101.36, this panel must include the serving size, number of servings per container, a list of all dietary ingredients, and the amount per serving. The front of the package must also identify the product as a “dietary supplement,” “herbal supplement,” “calcium supplement,” or a similar descriptive term.

Beyond the Supplement Facts panel, three types of claims are permitted under federal law:

• Health claims describe a relationship between a food substance and a disease or health condition, and they require FDA authorization.
• Structure/function claims describe how a nutrient or ingredient affects normal body structure or function (for example, “calcium builds strong bones”). These do not require FDA pre-approval but must be accompanied by a disclaimer stating the claim has not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease.
• Nutrient content claims describe the level of a nutrient in a product (for example, “high in vitamin C”).

What is explicitly prohibited: any claim that a supplement treats, prevents, cures, or alleviates the symptoms of a disease. Making such a claim classifies the product as a drug under the FD&C Act, triggering the full drug approval process. Labels must be truthful and not misleading; the FDA can remove a product from the market if its labeling fails that standard.

The FTC applies a parallel standard to advertising, requiring that marketing claims be truthful, not misleading, and backed by competent and reliable scientific evidence. Consumers who want to sharpen their ability to read these claims can find practical guidance on evaluating wellness product transparency.

Pro Tip: When you see a structure/function claim on a supplement label, look for the required FDA disclaimer. If it is missing, that is a red flag worth taking seriously before you buy.

Where the regulatory system falls short

The most significant gap in supplement regulation is structural: the FDA must prove a product is unsafe before it can restrict or remove it. That burden sits entirely on the agency, not the manufacturer. Products stay on shelves until adverse events accumulate enough to trigger enforcement action.

• The voluntary nature of consumer adverse event reporting means the FDA receives only a fraction of actual incidents.
• Rapidly evolving ingredient markets outpace the FDA’s capacity to evaluate new substances before they reach consumers.
• The NDI notification process, while required, does not involve FDA pre-approval; the agency can object, but the manufacturer can proceed unless the FDA takes formal action.
• An HHS Office of the Inspector General report concluded that the original voluntary adverse event reporting system provided inadequate data, detecting relatively few events and lacking sufficient medical and product detail to assess health risks.
• Resource constraints limit how many facility inspections the FDA can conduct each year.
• Industry self-regulatory initiatives and third-party certification programs fill some of the gap, but participation is voluntary and uneven across the market.

The result is a system that works reasonably well for established ingredients with long safety records, but struggles with novel compounds, high-dose formulations, and products that blur the line between supplements and drugs. Mycelia Link’s analysis of how the supplement industry lacks regulation goes deeper on the specific enforcement gaps that affect consumers today.

What you should actually do as a supplement consumer

The FDA’s reactive enforcement model places real responsibility on you as a consumer. Knowing how the regulatory system works is the first step; acting on that knowledge is the second.

• Consult a healthcare provider before starting any new supplement, particularly if you take prescription medications or have a chronic condition.
• Read the Supplement Facts panel carefully and check that all ingredients and amounts are clearly listed.
• Treat structure/function claims skeptically. They do not require FDA review, and the required disclaimer is easy to overlook.
• Look for products that have been tested by an independent third-party organization. Certifications from bodies such as NSF International or USP indicate that a product was tested for identity, purity, and potency.
• Report adverse effects to the manufacturer using the contact information on the label, and consider submitting a report directly to the FDA through CAERS.
• Use resources from the NIH ODS and the FDA’s own consumer pages to research ingredients before purchasing.
• Be cautious with products that make dramatic health claims or that are marketed primarily through social media influencers without transparent ingredient sourcing.

The ODS at NIH advises consumers to consult healthcare professionals specifically because supplement testing standards are less rigorous than those applied to prescription drugs. That is not a reason to avoid supplements altogether; it is a reason to choose them carefully.

What Mycelia Link sees in the supplement industry

Mycelia Link operates in a market where the gap between regulatory requirements and actual industry practice is wide enough to matter. The company’s focus on third-party tested products and transparent labeling is a direct response to what its research consistently surfaces: many supplement brands meet the legal minimum while falling short of what consumers actually need to make informed decisions.

• CGMP compliance is legally required, but audits show that manufacturing consistency varies considerably across the industry, particularly among smaller producers.
• Marketing language frequently pushes against the boundaries of permissible claims, using phrases that imply disease treatment without crossing the legal line explicitly.
• Proprietary blends, which list ingredients without individual amounts, are technically legal but make it impossible for consumers to evaluate dosing or compare products.
• Third-party testing closes the gap that CGMP alone cannot. It provides independent verification that a product contains what the label says, at the stated amounts, without undisclosed contaminants.

Mycelia Link’s commitment to accessible, high-quality wellness products means publishing full ingredient transparency and relying on third-party verification rather than marketing claims. For consumers exploring functional mushroom supplements, that transparency is especially relevant given how widely product quality varies in that category. The brand’s non-profit apparel line, which supports reforestation, reflects the same principle: accountability should be visible, not just claimed.

Pro Tip: Before buying any supplement, search the FDA’s warning letter database for the brand name. If the company has received a warning letter for false claims or CGMP violations, that history is public and searchable at fda.gov.

How other countries regulate supplements compared to the U.S.

The U.S. approach is notably permissive by international standards. Most peer regulatory systems require more from manufacturers before a product reaches consumers.

The European Union regulates food supplements under Directive 2002/46/EC, which establishes a harmonized list of permitted vitamins and minerals and the approved sources from which they may be manufactured. Products containing vitamins or minerals not on that approved list have been prohibited in the EU since August 2005. EU member states may also require manufacturers to notify national authorities before placing a supplement on the market, giving regulators earlier visibility than the U.S. system typically provides.

In Canada, the Natural Health Products Regulations require a product license before a natural health product can be sold. Manufacturers must submit evidence of safety, efficacy, and quality to Health Canada, which reviews applications before granting a license. That is a pre-market approval process, which is the opposite of the U.S. model.

Australia operates a two-tier system through the Therapeutic Goods Administration (TGA). Lower-risk products are listed on the Australian Register of Therapeutic Goods without full evaluation, but they must still meet quality and safety standards. Higher-risk products require full registration with evidence review.

The common thread across these systems is greater pre-market scrutiny than DSHEA provides. The U.S. model prioritizes market access and manufacturer responsibility; most other developed regulatory systems place more of the verification burden on the manufacturer before the product reaches a consumer’s hands. Neither approach eliminates risk entirely, but the practical difference for consumers is real: a supplement sold legally in the U.S. has cleared a lower bar than the same product would face in Canada or the EU.

Key Takeaways

The U.S. supplement regulatory system places legal responsibility for safety and labeling on manufacturers, not the FDA, making informed consumer choices the most reliable safeguard available.

Recommended

• How the Supplement Industry Lacks Regulation in 2026
• Why Contaminated Supplements Reach Shelves: 2026 Guide
• Functional Mushroom Supplements Explained: 2026 Guide
• Supplement Fatigue: What Every Consumer Should Know